Health economist
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Christopher McCabe
King's scientists to help build world's largest dark matter detector
Physicists from King's are working with universities across the UK to build an advanced dark matter detector ten times the size of the previous record holder. Physicists from King’s have begun work designing the world’s largest and most advanced dark matter detector, alongside other leading UK universities.
Long-read sequencing for fast and robust identification of correct genome-edited alleles: PCR-based and Cas9 capture methods
Loading metrics Open Access Peer-reviewed Research Article ? This is an uncorrected proof. Citation: McCabe CV, Price PD, Codner GF, Allan AJ, Caulder A, Christou S, et al. (2024) Long-read sequencing for fast and robust identification of correct genome-edited alleles: PCR-based and Cas9 capture methods. PLoS Genet 20(3): e1011187.
Mitigating anthropogenic and synanthropic noise in atom interferometer searches for ultralight dark matter
Atom interferometers offer promising new avenues for detecting ultralight dark matter (ULDM). The exceptional sensitivity of atom interferometers to fluctuations in the local gravitational potential exposes them to sources of noise from human (anthropogenic) and animal (synanthropic) activity, which may obscure signals from ULDM.
Canada’s misguided changes to drug regulation could fast-track unproven medications and divert funds from other health needs
By: Steven G. Morgan, Professor, School of Population and Public Health, University of British Columbia; Aidan Hollis, Professor of Economics, University of Calgary; Christopher McCabe, Professor of Health Economics, Queen's University Belfast; Matthew Herder,, The Conversation Tweet Print Email Save to Read Later This article was originally published on The Conversation, an independent and nonprofit source of news, analysis and commentary from academic experts.
Canada's misguided changes to drug regulation could fast-track unproven medications and divert funds from other health needs Original
The Canadian government is proposing a new “Agile Licensing” framework to expedite pre-market regulation of pharmaceuticals. While Health Minister Jean-Yves Duclos claims this is part of the government’s strategy to offer Canadians “access to quality and affordable medicines,” the policy is likely to cause more harm than good. Adoption of Agile Licensing would allow companies to market drugs up to six months earlier than under the current system.
Fueling the search for light dark matter-electron scattering with spherical proportional counters
Abstract Dark matter (DM) detectors employing a spherical proportional counter (SPC) have demonstrated a single-electron detection threshold and are projected to have small background rates. We explore the sensitivity to DM-electron scattering with SPC detectors in the context of darksphere, a proposal for a 300 cm diameter fully electroformed SPC. SPCs can run with different gases, so we investigate the sensitivity for five targets: helium, neon, xenon, methane, and isobutane.
Ultralight dark matter searches at the sub-Hz frontier with atom multigradiometry
Abstract Single-photon atom gradiometry is a powerful experimental technique that can be employed to search for the oscillation of atomic transition energies induced by ultralight scalar dark matter (ULDM). In the sub-Hz regime, the background is expected to be dominated by gravity gradient noise (GGN), which arises as a result of mass fluctuations around the experiment.
Markos v. Warraich et al
February 21, 2023 Filing 2 FIRST ORDER AND NOTICE REGARDING DISCOVERY AND SCHEDULING: ***NOTICE TO ATTORNEYS*** : Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, ALL Non-governmental CORPORATE parties must file a DISCLOSURE STATEMENT with the Court. Forms are available on the Court's Web Site at http://www.wvnd.uscourts.gov/forms.htm Rule 26 Meeting to be held by 3/21/2023. Rule 26 Meeting Report due by 4/4/2023. Discovery due by 4/18/2023.
OPINION | If we continue waiting for more evidence about omicron, it will already be too late | CBC News
The time to act was yesterday. Delta already poses a grave risk on its own, and now we face both delta and omicron, write Blake Murdoch and Christopher McCabe from the University of Alberta. People wearing face masks cross a street in Montreal. Even if omicron is less severe in the vaccinated and previously-infected communities, its high transmissibility means we should expect to see another substantial wave of severe disease, according to Blake Murdoch and Christopher McCabe.
King's physicists contribute to research into quantum technologies
King's is contributing to research in quantum technologies King’s Physicists are playing a key role in the Atom Interferometry Observatory and Network (AION) project, and the Quantum Simulators for Fundamental Physics (QSimFP) project launched by the UKRI Science Technologies and Facilities Council. King’s has established expertise in quantum technologies.
Balancing the Economics and Ethics of Personalised Oncology
Highlights Cost frameworks that assess drug value and balancing quality of life, efficacy, and price should also take into account the opportunity cost. This is the loss to a patient of potential benefits they could have received from an alternative treatment and can be measured in time, quality of life, or financial measures.
One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit
Open Access Practical Application First Online: 16 December 2019 Shares 77 Downloads Abstract Although probabilistic analysis has become the accepted standard for decision analytic cost-effectiveness models, deterministic one-way sensitivity analysis continues to be used to meet the need of decision makers to understand the impact that changing the value taken by one specific parameter has on the results of the analysis.
Understanding Harris’ understanding of CEA: Is cost effective resource allocation undone?
1. Miyamoto, JM , Eraker, SA. A Multiplicative Model of the Utility of Survival Duration and Health Quality. Journal of Experimental Psychology 1988; 117: 3–20. Google Scholar | Crossref 2. Torrance, G. Measurement of health state utilities for economic appraisal: A review. Journal of Health Economics 1986; 5: 1–30. Google Scholar | Crossref | Medline 3. Harris, J. The Value of Life. London: Routledge, 1985 Google Scholar 4. Harris, J. What is the good of health care. Bioethics 1996; 10: 269–91.
Faculty Annual Prize Giving 2018
Awards were made for contribution to life of the department, contribution to outreach activities and exceptional contribution to the academic progress of fellow students. Prizes were awarded for top grades in examinations, projects & laboratory work, best poster, best research, excellence in practical chemistry, greatest improvement and most promising potential for research.
Addendum: Low-value approvals and high prices might incentivize ineffective drug development
In hindsight, we realize that we could have been more precise when using the terms ‘profit’ and ‘revenue’ in our article ‘Low-value approvals and high prices might incentivize ineffective drug development’. Total revenue is defined as the receipts from sales1. Profit is defined as the excess of the receipts from sales over the spending of a business during any period1. Hence, profit is the total revenue minus the costs of a business, over a given period.
Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn’s Disease Reduces Costs Compared With Late Initiation
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Figure 1 (A) Model structure diagram representing the progression of a hypothetical cohort of patients with moderate-to-severe Crohn’s disease after initiating either early or late anti-TNF therapy.
NMS staff win in King's Teaching Excellence Awards
Two members of staff from the Faculty of Natural & Mathematical Sciences have been recognised in the King's Teaching Excellence Awards. Professor Luca Viganò (right) of the Department of Informatics won an Education Experience Award, while Dr Christopher McCabe (left) of the Department of Physics won in the Rising Star category. The Teaching Excellence Awards are highly competitive, and winning in any of the categories is an outstanding achievement.
Pitfalls of prioritizing cost-effectiveness in the assessment of medical innovation: A comment on Wallis and Detsky guest editorial
Obtain CPD Credit! CUAJ now provides readers with Section 3 credits of the Maintenance of Certification (self-assessment) program with the RCPSC. Read the accredited article, answer the multiple-choice questionnaire, and log the self-learning activity in your Royal College MAINPORT account.
Vote NO on Philly's best-value ballot question
On Tuesday, Philadelphia voters will be asked to vote on this ballot question: “Shall The Philadelphia Home Rule Charter be amended to allow for the award of certain contracts based on best value to the city?” Currently, Philadelphia awards most contracts under the “lowest responsible bid” standard, which generally means that the qualified bidder with the lowest price is awarded the contract.
Show drugs work before selling them
Illustration by David Parkins Under US President Donald Trump, defunct economic arguments about prescription drugs are coming to the fore. His advisers contend that today's system is a bad deal. They want to undo regulations that require companies to show that a medical product actually works before it is sold. The advisers argue that removing the burden of large, lengthy clinical trials will cut costs and reduce delays, and that the marketplace can be trusted to sort good drugs from bad ones.
PharmacoEconomics, Volume 35, Issue 1
Volume 35, Issue 1, January 2017 ISSN: 1170-7690 (Print) 1179-2027 (Online) In this issue (10 articles)
Cancer Drugs Fund 2.0: A Missed Opportunity?
Dillon, A. NICE calls for a new approach to managing the entry of drugs into the NHS. Press Release. NHS England, N. Consultation on proposals for a new cancer drugs fund (CDF) operating model from April 2016. 2015. Jack A. Which way now for the Cancer Drugs Fund? BMJ. 2014;349:g5524. Accessed 18 March 2016. Pharmaceutical Management Agency. Your guide to PHARMAC: setting and managing the combined pharmaceutical budget (CPB). [Fact Sheet 8] p. 1–2.Accessed 18 March 2016. Cookson R.
A Review of “The New Drug Reimbursement Game: A Regulator’s Guide to Playing and Winning”
JavaScript is currently disabled, this site works much better if you enable JavaScript in your browser.
Opinion: Let the genomic revolution prevail
Genomics research is already paying off in health-care technologies and treatments, writes Dr. Christopher McCabe. Continued public investment in that research has the potential to deliver health tretments at a cost Canadians can afford. Photograph by: Leah Hennel , Calgary Herald/file The scientific journal Nature published a series of papers earlier this year mapping the epigenome — roughly, the changes that affect how genes are expressed in our cells.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Christopher
Contact Christopher, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack